<DOC>
	<DOCNO>NCT00635284</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLTs ) ABI-009 give weekly ; characterize toxicity ABI-009 ; determine pharmacokinetic parameter ABI-009 give weekly schedule .</brief_summary>
	<brief_title>ABI-009 Trial Patients With Advanced Non-hematologic Malignancies</brief_title>
	<detailed_description>No extended description necessary</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Each subject must meet follow criterion enrol study . 1 . Male female patient histologically cytologically confirm diagnosis cancer amenable curative therapy . 2 . Patients advance nonhematologic malignancy standard therapy exists . 3 . Measurable disease RECIST evaluable disease ( e.g. , bone metastasis , pleural effusion , ascites , lesion fulfill RECIST criterion metastatic disease ) 4 . Off therapy ( inclusive investigational therapy ) least 4 week prior study drug administration OR daily weekly therapy ( inclusive investigational therapy ) least 2 week prior study drug administration without side effect associate therapy . 5 . Female patient childbearing potential must negative serum pregnancy test within 7 day prior first study drug administration . 6 . Female patient postmenopausal must 12 month amenorrhea , surgically sterile , must agree use physical method nonhormonal contraception . 7 . Male patient must surgically sterile agree use barrier method contraception . 8 . Life expectancy &gt; 3 month . 9 . ECOG Performance Status 01 . 10 . Patients must able provide inform consent indicate knowledge his/her disease process , investigational nature therapy , alternative , benefit , risk include potential side effect . 11 . Age ≥ 18 year age . 12 . No major surgery within 4 week treatment ABI009 . ( A biopsy consider major surgery ) . 13 . No chemotherapy , hormonal therapy , immunotherapy radiotherapy within 4 week treatment ABI009 ( 6 week previous treatment nitrosoureas , mitomycin , extensive radiotherapy ) immunosuppressive agent within 3 week study entry ( except corticosteroid use antiemetic ) . 14 . No immunosuppressive agent within 3 week study entry ( except corticosteroid use antiemetic ) . 15 . Required Initial Laboratory Data : Hemoglobin &gt; 9.0 g/dL WBC ≥ 3,000/µl ANC ≥ 1,500/µl Platelet count ≥ 100,000/µl Total Bilirubin ≤ ULN SGOT ( AST ) SGPT ( ALT ) ≤ 1.5 x ULN ≤ 1.5 x ULN Serum Cholesterol &lt; 350 mg/dL Serum Triglyceride &lt; 300 mg/dL 16 . Adequate renal function serum creatinine &lt; 1.5 mg/dL and/or creatinine clearance ( cockroft formula ) ≥ 60 mL/min . 17 . No active alcohol abuse , drug addiction , psychotic disorder . 18 . No known concomitant genetic acquire immunosuppressive disease ( AIDS ) . 19 . If obese , patient must treat dos calculate use his/her actual BSA ( The physician must comfortable treat full BSA dose regardless BSA ) . Subjects meet follow criterion exclude study . 1 . Pregnant nursing woman . 2 . History allergic reaction attribute compound similar chemical biologic composition include macrolide ( e.g . azithromycin , clarithromycin , dirithromycin , erythromycin ) ketolide antibiotic . 3 . Patients recover adverse affect radiation therapy investigational agent within previous 28 day . 4 . Uncontrolled intercurrent illness opinion investigator would limit compliance tolerance study requirement 5 . Patients know brain metastasis leptomeningeal tumor involvement . 6 . Receiving follow : concomitant antitumor therapy inhibitor CYP3A4 . 7 . Patients history interstitial lung disease and/or pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>